In conclusion, our data demonstrate that ANXA2 and the associated fibrinolytic pathway have highly differential roles for progression of BCR-ABL1+ B-ALL and CML versus MLL-AF9+ AML. Here, ANXA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.